Penumbra (PEN) Expected to Announce Quarterly Earnings on Wednesday

Penumbra (NYSE:PEN) is expected to be releasing its earnings data after the market closes on Wednesday, April 23rd. Analysts expect Penumbra to post earnings of $0.66 per share and revenue of $315.72 million for the quarter. Penumbra has set its FY 2025 guidance at EPS.Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Penumbra (NYSE:PEN) last posted its quarterly earnings results on Tuesday, February 18th. The company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.88 by $0.09. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. The company had revenue of $315.52 million for the quarter, compared to the consensus estimate of $311.63 million. On average, analysts expect Penumbra to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Penumbra Stock Up 0.7 %

NYSE:PEN opened at $272.10 on Wednesday. The company has a 50-day moving average of $274.64 and a 200 day moving average of $249.90. Penumbra has a 1-year low of $148.00 and a 1-year high of $310.00. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.01 and a quick ratio of 3.25. The firm has a market cap of $10.53 billion, a PE ratio of 800.30, a price-to-earnings-growth ratio of 2.83 and a beta of 0.56.

Wall Street Analysts Forecast Growth

PEN has been the topic of several recent analyst reports. StockNews.com downgraded shares of Penumbra from a “buy” rating to a “hold” rating in a report on Friday, February 28th. Morgan Stanley boosted their price objective on Penumbra from $240.00 to $260.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 19th. Piper Sandler restated an “overweight” rating and set a $330.00 price target (up previously from $250.00) on shares of Penumbra in a report on Wednesday, February 19th. Royal Bank of Canada restated an “outperform” rating and issued a $315.00 price objective on shares of Penumbra in a report on Tuesday. Finally, Bank of America began coverage on Penumbra in a research note on Friday, March 14th. They issued a “buy” rating and a $320.00 price objective for the company. Four investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $293.93.

Insider Activity

In other Penumbra news, Director Thomas Wilder sold 360 shares of Penumbra stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $264.58, for a total value of $95,248.80. Following the transaction, the director now owns 4,533 shares in the company, valued at approximately $1,199,341.14. The trade was a 7.36 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Johanna Roberts sold 600 shares of Penumbra stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $287.43, for a total value of $172,458.00. Following the completion of the transaction, the executive vice president now directly owns 66,539 shares in the company, valued at $19,125,304.77. This represents a 0.89 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 111,236 shares of company stock worth $31,222,390. 5.00% of the stock is currently owned by corporate insiders.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.